SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (22954)7/8/1998 7:25:00 PM
From: Henry Niman  Respond to of 32384
 
Mudcat, The LGND/LLY deal targets synergies between rexinoids and SERMs. I had the distinct impression that the primary focus was on second generation compounds (rexinoids like LGD1268 and LGD1324 from LGND and 2nd generation SERMs like LY353381*HCL from LLY).



To: Mudcat who wrote (22954)7/8/1998 7:47:00 PM
From: Henry Niman  Respond to of 32384
 
I could find the general statement:
"Additional rights to use Ligand technology to develop a compound in
combination with a Selective Estrogen Receptor Modulator (SERM) in cancer. " in various press releases and SEC filings. However, I think that somewhere there was an indication that the rexinoid would be a more advanced compound (not Targretin) as would the SERM (not Evista).


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News